Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.74 |
| ▸ | HTR1A | P08908 | 2/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.69 |
| ▸ | HTR2A | P28223 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.69 |
| ▸ | HTR2B | P41595 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370479 | 0.91 | REN (0.73) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3370472 | 0.91 | REN (0.73) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL5614264 | 0.88 | REN (0.71) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3371352 | 0.88 | REN (0.71) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3369437 | 0.88 | REN (0.71) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3369426 | 0.88 | REN (0.71) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3371153 | 0.86 | REN (0.72) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3371965 | 0.86 | REN (0.72) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL3369921 | 0.86 | REN (0.72) | RENHTR1AADRA1DHTR2AADRA1A | |
| SCHEMBL13177141 | 0.86 | REN (0.79) | RENHTR1AADRA1DHTR2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |